Patents by Inventor Niyada Hin

Niyada Hin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS
    Publication number: 20220119374
    Abstract: Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer or HIV-1, are provided.
    Type: Application
    Filed: January 29, 2020
    Publication date: April 21, 2022
    Inventors: Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit G. Thomas
  • Inhibitors of D-amino acid oxidase
    Patent number: 9505753
    Abstract: D-amino acid oxidase (DAAO) inhibitors and methods of their use, either alone or in combination with D-serine or D-alanine, to facilitate allosteric activation of NMDA receptor-mediated neurotransmission and methods of their use as therapeutic agents for treating a subject afflicted with one or more cognitive-disorders, such as schizophrenia, including subjects suffering from negative symptoms and cognitive impairments, post-traumatic stress disorder (PTSD), or pain, are disclosed.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: November 29, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Takashi Tsukamoto, Barbara Stauch Slusher, Dana V. Ferraris, Camilo Rojas, Niyada Hin, Bridget Duvall
  • INHIBITORS OF D-AMINO ACID OXIDASE
    Publication number: 20150218156
    Abstract: D-amino acid oxidase (DAAO) inhibitors and methods of their use, either alone or in combination with D-serine or D-alanine, to facilitate allosteric activation of NMDA receptor-mediated neurotransmission and methods of their use as therapeutic agents for treating a subject afflicted with one or more cognitive-disorders, such as schizophrenia, including subjects suffering from negative symptoms and cognitive impairments, post-traumatic stress disorder (PTSD), or pain, are disclosed.
    Type: Application
    Filed: August 8, 2013
    Publication date: August 6, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Takashi Tsukamoto, Barbara Stauch Slusher, Dana V. Ferraris, Camilo Rojas, Niyada Hin, Bridget Duvall